Envista Q1 sales rise, beat estimates on segment growth

Envista Holdings

06/05/2026 21:48

Overview

U.S. dental products maker's Q1 sales rose 14% yr/yr, beating analyst expectations

Adjusted diluted EPS grew 50% yr/yr to $0.36

Company announced new $300 mln share repurchase program

Outlook

Envista maintains full-year 2026 guidance for core sales growth of 2% to 4%

Company expects 2026 adjusted EBITDA growth of 7% to 13%

Envista sees 2026 adjusted diluted EPS of $1.35 to $1.45

Result Drivers

SEGMENT GROWTH - All major businesses delivered positive growth, with 8.4% core growth in Specialty Products & Technologies and 11.5% in Equipment & Consumables

OPERATIONAL IMPROVEMENTS - Margin expansion supported by broad-based contributions from the Envista Business System

Company press release: ID:nPn6XXsffa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$705.50 mln
$680.05 mln (13 Analysts)
Q1 Adjusted Net Income
$60 mln
Q1 Net Income
$39 mln
Q1 Adjusted EBITDA
$99 mln
Q1 Gross Profit
$390.10 mln
Q1 Operating Profit
$62.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Envista Holdings Corp is $29.50, about 12.6% above its May 5 closing price of $26.19

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 18 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)